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Summary. Immunostaining for bcl-2 protein was 
performed in 27 colorectal adenomas and 108 colorectal 
adenocarcinomas. The aim of the study was to determine 
bcl-2 expression in correlation with p53, mdm-2 and Rb 
expression, with proliferation indices (Ki-67-LI, PCNA- 
LI) as well as with conventional clinicopathological 
variables. A higher proportion of adenomas (30.8%) 
than carcinomas (16.7%) expressed bcl-2 and 
conversely, a lower proportion of adenomas (7.4%) than 
carcinomas expressed p53 (57.1 %), the difference being 
statistically significant (p<0.0001). No correlation of 
bcl-2 expression with p53 expression (parallel or 
inverse) as well as with the other parameters studied was 
observed in any tumour. The bcl-2+/p53- subgroup of 
cancers showed a trend for correlation with negative 
lymph node status. Our data suggest,  that bcl-2 
expression may be involved in the early phase of 
colorectal carcinogenesis regardless of p53 status, while 
p53 function may be involved in a late stage of the 
adenoma-carcinoma sequence. P53 is apparently not 
involved in the regulation of apoptosis in the colorectal 
neoplasias or perhaps bcl-2 expression, as an early event 
in colorectal tumours, may occur before changes of p53 
take place. Tumours with bcl-2+/p53- immunophenotype 
are frequently associated with negative lymph node 
status and seem to have a less aggressive behavior. 
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lntroduction 
Severa1 genetic aberrations have been implicated in 
tumorigenesis including activation of cellular 
protooncogenes or inactivation of tumour suppressor 
genes (Bishop, 1987). These alterations result in 
accelerated rates of cell division, decreased rates of cell 
death or both (McDonnell, 1993). 
Bcl-2 is an oncogene involved in the regulation of 
cell death by inhibiting programmed cell death in 
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physiological and neoplastic conditions (Reed, 1994). Its 
role, as a new kind of oncogene, has been primarily 
investigated in haematological malignancies and 
concretely in follicular B-cell lymphomas. In these 
lymphomas, overproduction of both bcl-2 mRNA and 
protein has been associated with a t(14;18) chromosomal 
translocation (Tsujimoto et al., 1985). Bcl-2 expression 
has also been investigated in non-lymphoid tissues, such 
as prostate (McDonell et al., 1992), lung (Ikegaki et al., 
1994), breast (Silvestrini et al., 1994), thyroid (Pilotti et 
al. ,  1994), ovarian (Henriksen et al., 1995) and 
endometrial (Chhieng et al., 1996) tumours, as well as in 
gastrointestinal tumours (Flohil et al., 1996; Krajewska 
et al., 1996; Watson et al., 1996; Yao et al., 1999). 
Other important genes that play a role in the 
regulation of apoptosis are the tumour suppressor genes 
p53 and Rb (Hooper, 1994);  the latter has been 
suggested to induce apoptosis via p53. Wild-type p53 
has been demonstrated to induce apoptosis (Ginsberg et 
al., 1991) and the bcl-2 gene is a transcriptional target 
for wild-type p53 which decreases bcl-2 protein levels 
both in  vitro and ir1 vivo (Miyashita et al., 1994). 
Furthermore, mutant p53 has been shown to inhibit bcl-2 
expression in some cancer cell lines (Haldar et al., 
1994). There is now a growing list of proteins which 
potentially involve p53 in pathway which regulate 
apoptosis. One of these proteins is the murine double- 
minute-2 (mdm-2) gene product that has been shown to 
couple wild-type and mutant p53 protein bringing about 
function inactivation of the p53 gene (Wu et al., 1993). 
Recently, some studies in colorectal tumours have 
revealed evidence of the adenoma-carcinoma sequence 
with regard to bcl-2 and p53 overexpression. It has been 
reported that bcl-2 expression was reduced in 
carcinomas compared with adenomas (Flohil et al., 
1996), suggesting a down-regulation of its expression 
when adenomas progress to carcinomas. In addition, bcl- 
2 expression has also been described as being associated 
with a better prognosis in cases of colorectal carcinomas 
(Ofner et al., 1995). Mutation and overexpression of p53 
occurs late in colorectal carcinogenesis before the 
transition of an adenoma to a carcinoma and p53 protein 
accumulation has been associated with an aggressive 
behavior of colon carcinomas (Smith et al., 1996). 
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Furthermore, p53 expression has been reported to be 
inversely correlated with bcl-2 expression in colorectal 
tumours (Watson et al., 1996; Hao et al., 1998). 
The aim of this study was to examine bcl-2 
expression in a series of colorectal adenomas and 
carcinomas, in an attempt to clarify the role of this gene 
in the development and progression of colorectal 
tumours. We also searched for a possible correlation 
between bcl-2 expression and p53, mdm-2, Rb 
expression as well as with proliferation indices (Ki-67, 
PCNA) and clinicopathological data (age, sex, tumour 
size, grade and Dukes' stage). 
Materials and rnethods 
A total of 27 colorectal adenomas and 108 colorectal 
adenocarcinomas were obtained either from surgical 
resection specimens or by endoscopic biopsy. Specimens 
were collected shortly after surgery and were snap 
frozen in isopentane liquid nitrogen using an embedding 
medium for frozen tissue specimens, O.C.T. compound 
(Tissue Tek-Miles). The frozen specimens were stored at 
-80 "C until processing. One parallel sample was fixed in 
10% formalin for 24 hours and was subsequently 
processed with routine techniques and embedded in 
paraffin. Histological slides from paraffin-embedded 
tumour tissue were classified according to their 
pathological features following the World Health 
Organization (WHO) criteria (Jass and Sobin, 1989). 
Thus, according the histological growth type of 
adenomas, they were separated into three categories: 
tubular [n=14 (52%)], villous [n=4 (15%)] and tubulo- 
villous [n=9 (33%)]. With regard to the grade of 
dysplasia, there were 18  adenomas (67%) with low 
grade (mild, moderate) dysplasia and 9 adenomas (33%) 
with high grade (severe) dysplasia. Histologically, al1 
colorectal carcinomas were adenocarcinomas. The age 
of the patients at time of surgery ranged from 26 to 86 
years old. According to the WHO criteria, the tumour 
grade was high in 26 cases (24%), moderate in 73 cases 
(68%) and low in 9 cases (8%). In addition, according to 
Dukes' stage there were 11 cases of stage A (lo%), 54 
cases of stage B (50%) and 43 cases of stage C (40%). 
Immunohistochemical analysis was performed on 
5ym tissue sections by the Avidin-Biotin Complex 
immunoperoxidase (ABC) technique. In brief, sections 
were deparaffinized in xylene and dehydrated. To 
unmask the epitopes of bcl-2, we microwaved the 
sections in lOmM citrate buffer, pH 6.0, whereas to 
unmask the epitopes of p53, mdm-2 and Rb, we 
microwaved the sections in T buffer. PCNA unmasking 
was achieved without using the heat-mediated antigen 
retrieval method. Then, the sections were treated with 
0.3% hydrogen peroxide (H202) in methanol for 30 min 
to block endogenous peroxidase. Sect ions were 
incubated for 20 min with normal serum and 
subsequently the sections were incubated overnight with 
the primary monoclonal antibodies, anti-bcl-2 (M0887, 
Dako, diluted 1:40), anti-p53 (DO-7, IgG2b, Dako, 
diluted 1:80), anti-mdm-2 (Ab-1, Oncogene, diluted 
1530) and anti-Rb (Ab-5, Oncogene, diluted 1:80), while 
the incubation with anti-PCNA (PC-10, Dako, diluted 
150)  was 1 hour. After a PBS washing, the preparations 
were incubated with biotinylated anti-mouse IgG. The 
three-step immunoperoxidase technique using ABC 
(Dako) was performed according to the procedure 
described by Hall et al. (1990). The staining colour was 
developed with diaminobenzidine. Thereafter, the 
sections were lightly counterstained with Mayer's 
haematoxylin and mounted. 
For Ki-67 immunostaining, 5 ym-thick frozen 
cryostat sections were air-dried, fixed in absolute 
acetone and stained using a sensitive two-step indirect 
immunoperoxidase technique. The sections were 
incubated with monoclonal antibody against Ki-67 
(Dako, diluted 1:lO) for 30 min in a moist chamber. 
After  washing in PBS, the frozen sections were 
incubated for 30 min with a rabbit anti-mouse and for 
another 30 min with a swine anti-rabbit peroxidase 
conjugate. A diaminobenzidine-H202 substrate was used 
to visualize the immunoreactivity. 
Bcl-2 immunostaining was scored as the percentage 
of cells exhibiting definite cytoplasmic 
immunoreactivity in at least 2000 neoplastic cells 
encountered in 20 representative high-power fields. 
Immunoreaction of bcl-2 was defined as negative when 
few ( 4 % )  of cells were positive, positive when a few to 
many (5-50%) of cells were positive and positive when 
many to al1 (>50%) of cells were positive. 
Immunoreactivity for p53 and Rb was scored as follows: 
no immunoreactivity or positive staining in less than 5% 
of tumour cells; positive staining in 5-50% of tumour 
cells with a mainly foca1 distribution; positive staining in 
more than 50% positive tumour cells. Because a few 
cases displayed nuclear positivity for mdm-2, every 
stained nucleus was considered positive, irrespectively 
of intensity, and therefore, tumours were classified as 
mdm-2 negative and mdm-2 positive. The evaluation of 
Ki-67 and PCNA immunostaining was calculated as the 
percentage of positive tumour cells in relation to the 
total number (about 1000) of tumour cells.  The 
percentage of positively-stained cells was recorded as 
Ki-67-LI (labelling index) and PCNA-LI and for 
statistical analysis the cases were divided into two 
groups ( 4 0 %  and >50% of cells positive) according to 
the estimated number of positive cells. The expression of 
Ki-67 was evaluated only in 68 from the 108 cases of 
adenocarcinomas. 
Al1 tumours were independently scored by two 
observers. Statistical evaluation was confirmed using 
non parameter test for two or severa1 independent 
samples or  Spearman bivariable correlation. 
Multivariate analysis was carried out by the Cox model. 
A p value below 0.05 was regarded as statistically 
significant. 
Results 
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Tsible 2. Bcl-2 expression and potential prognostic variables in 
colorectal carcinornas. 
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areas of moderate and severe dysplasia and 65 cases of 
adenocarcinomas (57.1%) having the evidence of p53 
nuclear overexpression. This  difference of p53 
immunostaining between adenomas and carcinomas was 
statistically significant (pc0.0001), but there was no 
statistical correlation between bcl-2 expression and p53 
immunoreactivity in any of these tumours (Table 2). 
Conversely, the bcl-2+/p53- subgroup showed a trend for 
correlation with negative lymph node status. Mdm-2 
expression was detected in 10.8% of adenocarcinomas 
investigated and only two cases of adenomas had a small 
number of mdm-2-positive cells (~10%).  Both of these 
cases were tubular and of low grade dysplasia. Rb 
protein was expressed in 54.5% of adenocarcinomas and 
in 76.9% of adenomas. Of these positive adenomas 7 
were villous, 8 tubular and 5 tubulovillous of low and 
moderate dysplasia. Neither mdm-2 nor Rb protein 
expression was correlated with bcl-2 expression. The 
mean value of Ki-67 and PCNA index was higher in 
carcinomas (45.54216 and 67.54121.74 respectively) 
than in adenomas (29.8213 and 30.17225.34 
respectively). No statistically significant correlation 
between the proliferative activity and bcl-2 expression 
was observed in either adenomas or qarcinomas. 
Dlscussion 
Sequential studies of transformation in a variety of 
colorectal lesions (ranging from reactive to neoplastic or 
from adenoma to carcinoma) indicate that carcinogenesis 
is a multistep process involving mutation. This includes 
the activation of oncogenes inducing growth promotion, 
as well as inactivation of growth suppressor genes. The 
final consequence of this genetic dysregulation is the loss 
of control of cell proliferation and differentiation. During 
the past decade, apoptosis has attracted more interest 
than any other biomedical field. The reason for this 
research focus on apoptosis is not only because it 
represents an important biological principie in tissue 
development and homeostasis, but also that its regulation 
appears to be perturbed in severa1 major diseases, 
including cancer (Reed, 1997). One of the most 
important developments in apoptosis research, has been 
the identification of the roles played by a variety of 
oncogenes and suppressor genes (bcl-2, c-myc, ras, p53, 
Rb). In this study we investigated the expression of bcl-2 
protein in a series of benign and malignant epithelial 
colorectal tumours. Moreover, we studied the correlation 
of bcl-2 with p53 accumulation, Rb and mdm-2 protein 
expression as well as with proliferative activity and 
conventional clinicopathological parameters. Though 
many details are missing, we are beginning to understand 
the biological mechanism of bcl-2 action (Wang and 
Reed, 1998). Several studies have suggested the possible 
role of bcl-2 for the regulation of cellular events in 
normal tissue and as a possible initial step toward 
malignancy in multistep carcinogenesis. In colonic 
tissue, the physiological expression of bcl-2 protein is 
confined especially to the stem cells and at the base of 
crypts (Hockenbery et al., 1991; Hague et al., 1994). 
Evidently, the role of bcl-2 is to protect the stem cells 
and for the renewal and repair abilities of the epithelium 
from apoptosis (Hockenbery et al., 1991). There are 
studies which suggest that the majority of colorectal 
cancers express bcl-2 (Hague et al., 1994), while in other 
studies this expression is observed in a lower proportion 
(Ofner et al., 1995). Sinicrope et al. (1995) reported the 
first  data concerning the importance of bcl-2 in 
colorectal tumorigenesis: in 71% of adenomas and in 
67% of adenocarcinomas, bcl-2 immunoreactivity was 
detected. Similar results have been reported in other 
studies although the reduction of bcl-2 expression in 
carcinomas compared with adenomas was more apparent 
(Hao et al., 1997). There are also data which suggest, 
that bcl-2 expression and a low rate of apoptosis were 
seen more often in villous than tubular adenomas. These 
studies suggest, that bcl-2 is involved in the prevention 
of apoptosis in large bowel epithelium and that, if 
overexpression is important in the carcinogenetic 
process, it probably occurs as an early event. 
In our study, we found that a lower proportion of 
adenomas and carcinomas expressed bcl-2 protein: in 
30.8% of adenomas and in 16.7% of cancers bcl-2 
immunostaining was observed. In comparison to other 
studies, we had discrepancies in our results. Perhaps 
these discrepancies may be related to differences in 
methodological procedures. However, in al1 studied 
cases, bcl-2 immunoreactivity in lymphocytes was used 
as an interna1 positive control. In good accordance with 
the observations published recently (Watson et al., 
1996), no relation was found between bcl-2 
immunoreactivity and histological growth type and 
grade of atypialdysplasia of adenomas. In addition, in 
the group of adenocarcinomas no relationship was 
Bcl-2 in colorectal tumours 
observed between bcl-2 immunostaining and patient's 
age or sex, tumour size, grade and stage (Table 1). 
The nuclear accumulation of p53 protein has been 
reported in many kinds of tumours, including colorectal 
cancer, in relation to p53 gene mutations (Costa et al., 
1995). In the colon,  p53 mutations are detected 
frequently in invasive carcinomas and rarely in 
adenomatous polyp, (Ichii et al., 1993; Houlston and 
Tomlinson, 1997). In a recent study, concerning analysis 
of genet ic  alterations in adenomas of familiar 
adenomatosis polyposis, p53 mutations have been 
reported in only two of 76 adenomas with moderate and 
severe dysplasia (Ichii et al., 1993). These results 
suggest, that inactivation of the p53 gene are associated 
with later events, such as malignant transformation or 
~ r o ~ r e s s i o n  to carcinomas. Recent work indicates that 
an Tmportant aspect of p53 function involves the 
induction of apoptosis, and it now appears clear that 
mutations in p53 promote tumorigenesis by interfering 
with programmed cell death. There are reports which 
argue that p53 may induce apoptosis, at least in part, by 
regulating transcription of bcl-2 family members. Under 
certain conditions, p53 induction leads to up-regulated 
expression of the apoptosis-promoting protein Bax, 
whilst a death-repressing member of the same protein 
family, bcl-2, is down-regulated (Miyashita et al., 
1994): indeed a p53-dependent negative response 
element has been identified in the bcl-2 gene. 
P53 expression has been reported to be inversely 
correlated with bcl-2 expression in colorectal adenomas 
and carcinomas (Watson et al., 1996; Hao et al., 1998), 
while another study has suggested that this correlation is 
confined only in adenomas (Sinicrope et al., 1995). In 
the current study, to  minimize the possibility of 
registering overexpression of wild-type p53, only cases 
with 5% or more of tumour cells showing distinctive 
nuclear s taining were regarding a s  positive. 
Overexpression of p53 protein was found in 7.4% of 
adenomas and in 57.1% of adenocarcinomas studied. In 
comparison with adenomas,  the rate of aberrant 
immunohistochemical p53 expression in carcinomas 
was statistically significantly higher. In accordance with 
results from other s tudies  in colorectal tumours 
(Baretton et al., 1996; Yao et al., 1999), we found no 
statistical correlation between bcl-2 and p53 
accumulation in both adenomas and carcinomas. These 
observations probably mean that p53 is apparently not 
involved in the regulation of apoptosis in the colorectal 
neoplasias or perhaps, that bcl-2 expression, as an early 
event in colorectal tumours, may occur before changes 
of p53 take place. On the other hand, in the series of 
carcinomas there was a trend for correlation between 
the bcl-2+/p53- subgroup with negative lymph node 
status. I t  is possible that tumours with bcl-2+/p53- 
phenotype imply a less aggressive pathway of 
neoplastic transformation. 
Nuclear mdm-2 protein immunoreactivity was 
observed in 10.8% of adenocarcinomas while only two 
cases of adenomas had a small number of positive 
neoplastic cells. Heterogenous nuclear staining for Rb 
protein was detected in 54.5% of adenomas and in 
76.9% of adenocarcinomas. Neither protein was 
correlated with bcl-2 expression of any tumours. 
Perhaps, these proteins contribute in different ways to 
the regulation of apoptosis. 
The proliferative activity, as measured by Ki-67 and 
PCNA immunoreactivity, increased significantly on 
progression from adenoma to carcinoma, but did not 
vary significanly within the separate adenoma and 
carcinoma groups. It has been reported that in the series 
of colorectal carcinomas the grade of Ki-67 index was 
correlated in a statistically significant manner with the 
rate of apoptotic cells (Baretton et al., 1996). These 
observat ions support  the idea that increased 
proliferation is  often accompanied by increased 
apoptosis. In our study, although a trend toward an 
inverse correlation between bcl-2 with Ki-76 and PCNA 
index was found, no statistically significant correlation 
between these parameters was observed in either 
adenomas or carcinomas. 
In conclusion, bcl-2 protein is expressed in 
colorectal adenomas and carcinomas with a higher 
incidence in adenomas. This fact probably means, that 
bcl-2 expression is characteristic of the early stage of 
colorectal tumorigenesis. Since bcl-2 expression did not 
correlate with p53 status, it can be concluded that in 
these tumors the regulation of apoptosis is quite 
complex and cannot  simply be reduced to the 
assessment of bcl-2 gene expression or p53 
accumulation. However, in bcl-2+/p53- cancers , the 
strong but not statistically significant correlation 
between this phenotype and negative lymph node status 
shows,  that there is a subgroup of colorectal 
adenocarcinomas which may have a better biological 
behavior. Further studies, perhaps of other regulators of 
apoptosis, are required before the value oí' bcl-2, as 
prognostic indicator, is established. In addition, as more 
anti-apoptotic mechanisms are uncovered, new potential 
therapeutic targets will be defined which should enable 
a more effective and more specif ic  treatment of 
colorectal cancer. The elucidation of these mechanisms 
is an interesting issue for future investigation. 
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